$ACAD
ACADIA PHARMACEUTICALS INC

2012 Q3 Form 10-Q Financial Statement

#000119312512344007 Filed on August 08, 2012

View on sec.gov

Income Statement

Concept 2012 Q3 2012 Q2 2011 Q2
Revenue $3.478M $599.0K $460.0K
YoY Change 495.55% 30.22% -80.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.500M $1.600M $1.000M
YoY Change 0.0% 60.0% -37.5%
% of Gross Profit
Research & Development $4.400M $4.472M $4.315M
YoY Change 5.82% 3.64% -13.7%
% of Gross Profit
Depreciation & Amortization $30.00K $60.00K $40.00K
YoY Change 0.0% 50.0% -71.43%
% of Gross Profit
Operating Expenses $5.885M $6.028M $7.044M
YoY Change 3.66% -14.42% 6.73%
Operating Profit -$2.407M -$5.429M -$6.584M
YoY Change -52.74% -17.54%
Interest Expense $5.000K $10.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$2.400M -$5.400M -$6.600M
YoY Change -52.94% -18.18% 53.49%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.402M -$5.419M -$6.556M
YoY Change -52.68% -17.34% 52.47%
Net Earnings / Revenue -69.06% -904.67% -1425.22%
Basic Earnings Per Share
Diluted Earnings Per Share -$44.53K -$101.9K -$125.2K
COMMON SHARES
Basic Shares Outstanding 53.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2012 Q3 2012 Q2 2011 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.10M $21.30M $40.40M
YoY Change -36.19% -47.28% 17.78%
Cash & Equivalents $8.016M $9.208M $8.020M
Short-Term Investments $15.00M $12.10M $32.30M
Other Short-Term Assets $600.0K $400.0K $700.0K
YoY Change 0.0% -42.86% -36.36%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $23.69M $21.78M $41.00M
YoY Change -35.64% -46.89% 7.05%
LONG-TERM ASSETS
Property, Plant & Equipment $63.00K $92.00K $200.0K
YoY Change -68.5% -54.0% -71.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.000K $7.000K $100.0K
YoY Change -98.0% -93.0% -50.0%
Total Long-Term Assets $65.00K $99.00K $300.0K
YoY Change -67.5% -67.0% -66.67%
TOTAL ASSETS
Total Short-Term Assets $23.69M $21.78M $41.00M
Total Long-Term Assets $65.00K $99.00K $300.0K
Total Assets $23.75M $21.87M $41.30M
YoY Change -35.81% -47.04% 5.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.131M $757.0K $1.100M
YoY Change -13.0% -31.18% -52.17%
Accrued Expenses $4.686M $5.225M $4.000M
YoY Change 6.5% 30.63% -2.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $6.086M $6.760M $5.900M
YoY Change -4.91% 14.58% -54.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $2.400M $2.500M
YoY Change -100.0% -4.0% -89.13%
Total Long-Term Liabilities $0.00 $2.400M $2.500M
YoY Change -100.0% -4.0% -89.18%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.086M $6.760M $5.900M
Total Long-Term Liabilities $0.00 $2.400M $2.500M
Total Liabilities $6.086M $9.166M $8.500M
YoY Change -31.62% 7.84% -76.39%
SHAREHOLDERS EQUITY
Retained Earnings -$360.9M -$358.5M
YoY Change
Common Stock $6.000K $5.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $17.66M $12.71M $32.82M
YoY Change
Total Liabilities & Shareholders Equity $23.75M $21.87M $41.30M
YoY Change -35.81% -47.04% 5.36%

Cashflow Statement

Concept 2012 Q3 2012 Q2 2011 Q2
OPERATING ACTIVITIES
Net Income -$2.402M -$5.419M -$6.556M
YoY Change -52.68% -17.34% 52.47%
Depreciation, Depletion And Amortization $30.00K $60.00K $40.00K
YoY Change 0.0% 50.0% -71.43%
Cash From Operating Activities -$5.310M -$4.800M -$5.280M
YoY Change 27.34% -9.09% -16.72%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$2.740M $8.390M $6.430M
YoY Change -161.16% 30.48% -332.97%
Cash From Investing Activities -$2.740M $8.390M $6.430M
YoY Change -161.16% 30.48% -332.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.800M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.860M 60.00K 50.00K
YoY Change -68700.0% 20.0% -145.45%
NET CHANGE
Cash From Operating Activities -5.310M -4.800M -5.280M
Cash From Investing Activities -2.740M 8.390M 6.430M
Cash From Financing Activities 6.860M 60.00K 50.00K
Net Change In Cash -1.190M 3.650M 1.200M
YoY Change -496.67% 204.17% -113.03%
FREE CASH FLOW
Cash From Operating Activities -$5.310M -$4.800M -$5.280M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-35000
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
57000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-117000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8727000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13857000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
33156000
us-gaap Operating Expenses
OperatingExpenses
13340000
us-gaap Revenues
Revenues
895000
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8020000
CY2011Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0.35 shares
CY2011Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.38
CY2011Q1 acad Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
4397904 shares
CY2011Q1 acad Warrants Expiration Month And Year
WarrantsExpirationMonthAndYear
2018-01
CY2012Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53030009 shares
CY2012Q1 acad Commission Rate
CommissionRate
0.03 pure
CY2012Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2012Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92000
CY2012Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
426000
CY2012Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7000
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
12708000
CY2012Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3600000
CY2012Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
302000
CY2012Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2012Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
495000
CY2012Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53030009 shares
CY2012Q2 us-gaap Liabilities
Liabilities
9166000
CY2012Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
757000
CY2012Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
12141000
CY2012Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
765000
CY2012Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-358508000
CY2012Q2 us-gaap Assets
Assets
21874000
CY2012Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21874000
CY2012Q2 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
13000
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9208000
CY2012Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
21117000
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53030009 shares
CY2012Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
3000
CY2012Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5225000
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6760000
CY2012Q2 us-gaap Common Stock Value
CommonStockValue
5000
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2012Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2406000
CY2012Q2 us-gaap Assets Current
AssetsCurrent
21775000
CY2012Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2012Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
371208000
CY2012Q2 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
4428000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6849000
CY2011Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
901000
CY2011Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
23362000
CY2011Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2011Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
333000
CY2011Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2011Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
679000
CY2011Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52898659 shares
CY2011Q4 us-gaap Liabilities
Liabilities
8752000
CY2011Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1960000
CY2011Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
24159000
CY2011Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
669000
CY2011Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2011Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-346871000
CY2011Q4 us-gaap Assets
Assets
32114000
CY2011Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32114000
CY2011Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
32000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6889000
CY2011Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
30729000
CY2011Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52898659 shares
CY2011Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9000
CY2011Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3504000
CY2011Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6165000
CY2011Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2011Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2011Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2587000
CY2011Q4 us-gaap Assets Current
AssetsCurrent
31949000
CY2011Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2011Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2011Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2011Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
151000
CY2011Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
370219000
CY2011Q4 acad Accrued Clinical Development Services
AccruedClinicalDevelopmentServices
2492000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-45000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12445000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-851000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13914000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12891000
us-gaap Share Based Compensation
ShareBasedCompensation
789000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
30843000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
us-gaap Investment Income Net
InvestmentIncomeNet
56000
us-gaap Other Noncash Expense
OtherNoncashExpense
806000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10387000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2313000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-79000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1171000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4613000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-219000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51535000 shares
us-gaap Depreciation
Depreciation
225000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2319000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3216000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-8000
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
19000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-475000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y183D
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9493000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
79000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
9838000
us-gaap Operating Expenses
OperatingExpenses
12709000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-103000
us-gaap Revenues
Revenues
1049000
us-gaap Depreciation
Depreciation
59000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9595000 shares
us-gaap Net Income Loss
NetIncomeLoss
-12389000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
14000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
786000
dei Trading Symbol
TradingSymbol
ACAD
dei Entity Registrant Name
EntityRegistrantName
ACADIA PHARMACEUTICALS INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2012
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0001070494
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Operating Income Loss
OperatingIncomeLoss
-11660000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1203000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
98000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11643000
us-gaap Share Based Compensation
ShareBasedCompensation
891000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
22005000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
103000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
us-gaap Investment Income Net
InvestmentIncomeNet
23000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10030000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12270000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-85000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
156000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52932000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11388000 shares
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2012Q2 us-gaap Share Based Compensation
ShareBasedCompensation
478000
CY2012Q2 us-gaap Investment Income Net
InvestmentIncomeNet
10000
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1556000
CY2012Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5422000
us-gaap Net Income Loss
NetIncomeLoss
-11637000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1721000
CY2011Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13900000
CY2011Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
12565446 shares
CY2011Q1 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
1.19375
CY2011Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6584000
CY2011Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7083000
CY2011Q2 us-gaap Share Based Compensation
ShareBasedCompensation
413000
CY2011Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2011Q2 us-gaap Investment Income Net
InvestmentIncomeNet
28000
CY2011Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2729000
CY2011Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4315000
CY2011Q2 us-gaap Operating Expenses
OperatingExpenses
7044000
CY2011Q2 us-gaap Revenues
Revenues
460000
CY2011Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52677000 shares
CY2011Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10285000 shares
CY2011Q2 us-gaap Net Income Loss
NetIncomeLoss
-6556000
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5429000
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4472000
CY2012Q2 us-gaap Operating Expenses
OperatingExpenses
6028000
CY2012Q2 us-gaap Revenues
Revenues
599000
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52961000 shares
CY2012Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11833000 shares
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-5419000

Files In Submission

Name View Source Status
0001193125-12-344007-index-headers.html Edgar Link pending
0001193125-12-344007-index.html Edgar Link pending
0001193125-12-344007.txt Edgar Link pending
0001193125-12-344007-xbrl.zip Edgar Link pending
acad-20120630.xml Edgar Link completed
acad-20120630.xsd Edgar Link pending
acad-20120630_cal.xml Edgar Link unprocessable
acad-20120630_def.xml Edgar Link unprocessable
acad-20120630_lab.xml Edgar Link unprocessable
acad-20120630_pre.xml Edgar Link unprocessable
d359784d10q.htm Edgar Link pending
d359784dex311.htm Edgar Link pending
d359784dex312.htm Edgar Link pending
d359784dex321.htm Edgar Link pending
d359784dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending